Physician profile
Mujtaba Qureshi
NPI 1043880503
$9,514.10
in general payments reported to CMS, 2019-2025
11 companies · $5,314 in 2025
The $5,314 reported for 2025 was more than what 96% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,200 · 2025: $5,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,304 · Food and Beverage: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,304.07 |
| Food and Beverage | $3,210.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,694.61 | 2024-2025 | Ortholoc 3di, Hoffmann, Prostep |
| Paragon 28, INC. | $1,653.39 | 2024-2025 | Portfolio, Monkey Rings, Gorilla |
| Orthofix Medical, INC. | $1,530.46 | 2024 | Truelok |
| Arthrex, INC. | $1,314.46 | 2025 | |
| Extremity Medical | $506.95 | 2024 | |
| Seapearl East, INC | $401.73 | 2025 | |
| Integra Lifesciences Corporation | $187.59 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bard Peripheral Vascular, INC. | $154.35 | 2025 | Rotarexs 6 F X 135 Cm |
| Averitas Pharma INC. | $29.73 | 2025 | Qutenza |
| Organogenesis INC. | $24.00 | 2024 | |
| Acadia Pharmaceuticals INC | $16.83 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mujtaba Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.